| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L M Rings, A M Kamr, H M Kinsella, L D Hostnik, J M Swink, T A Burns, K Christie, J B David, R E Toribi. The enteroinsular axis during hospitalization in newborn foals. Domestic animal endocrinology. vol 78. 2021-12-09. PMID:34649126. |
the goals of this study were to measure serum insulin and plasma incretin (glucose-dependent insulinotropic polypeptide [gip], glucagon-like peptide-1 [glp-1] and glucagon-like peptide-2 [glp-2]) concentrations, to determine the insulin and incretin association, as well as their link to disease severity and outcome in hospitalized foals. |
2021-12-09 |
2023-08-13 |
Not clear |
| L M Rings, A M Kamr, H M Kinsella, L D Hostnik, J M Swink, T A Burns, K Christie, J B David, R E Toribi. The enteroinsular axis during hospitalization in newborn foals. Domestic animal endocrinology. vol 78. 2021-12-09. PMID:34649126. |
blood samples were collected over 72 h to measure serum insulin and plasma gip, glp-1 and glp-2 concentrations using immunoassays. |
2021-12-09 |
2023-08-13 |
Not clear |
| L M Rings, A M Kamr, H M Kinsella, L D Hostnik, J M Swink, T A Burns, K Christie, J B David, R E Toribi. The enteroinsular axis during hospitalization in newborn foals. Domestic animal endocrinology. vol 78. 2021-12-09. PMID:34649126. |
at admission, serum glucose and insulin and plasma gip were significantly lower in hospitalized and septic compared to healthy foals (p < 0.01), while plasma glp-1 and glp-2 concentrations were higher in hospitalized and septic foals than healthy and sns foals, and decreased over time in septic foals (p < 0.05). |
2021-12-09 |
2023-08-13 |
Not clear |
| L M Rings, A M Kamr, H M Kinsella, L D Hostnik, J M Swink, T A Burns, K Christie, J B David, R E Toribi. The enteroinsular axis during hospitalization in newborn foals. Domestic animal endocrinology. vol 78. 2021-12-09. PMID:34649126. |
hospitalized foals with serum insulin < 5.8 µiu/ml, plasma glp-1 >68.5 pm, and plasma glp-2 >9 ng/ml within 24 h of admission were more likely to die (or = 4.2; 95% ci = 1.1-16.1; or = 13.5, 95% ci = 1.4-123.7; or = 12.5, 95% ci = 1.6-97.6, respectively; p < 0.05). |
2021-12-09 |
2023-08-13 |
Not clear |
| L M Rings, A M Kamr, H M Kinsella, L D Hostnik, J M Swink, T A Burns, K Christie, J B David, R E Toribi. The enteroinsular axis during hospitalization in newborn foals. Domestic animal endocrinology. vol 78. 2021-12-09. PMID:34649126. |
low gip together with increased glp-1 and glp-2 concentrations indicates that different mechanisms may be contributing to reduced insulin secretion in critically ill foals, including impaired intestinal production (gip, proximal intestine) and pancreatic endocrine resistance to enhanced incretin secretion (glp-1, glp-2; distal intestine). |
2021-12-09 |
2023-08-13 |
Not clear |
| J Michael Conlon, Finbarr P M O'Harte, Peter R Flat. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review. Peptides. vol 147. 2021-12-09. PMID:34861327. |
proglucagon-derived peptides from phylogenetically ancient fish act as naturally occurring dual agonists at the glp1r and the glucagon receptor (gcgr) with lamprey glp-1 and paddlefish glucagon being the most potent and effective in stimulating insulin release from brin-bd11 clonal β-cells. |
2021-12-09 |
2023-08-13 |
mouse |
| Katarzyna Głombik, Jan Detka, Bogusława Budziszewsk. Hormonal Regulation of Oxidative Phosphorylation in the Brain in Health and Disease. Cells. vol 10. issue 11. 2021-12-08. PMID:34831160. |
this review aims to expound on the impact of hormones (glp-1, insulin, thyroid hormones, glucocorticoids) on metabolic processes in the brain with special emphasis on oxidative phosphorylation dysregulation, which may contribute to the formation of pathological changes. |
2021-12-08 |
2023-08-13 |
Not clear |
| Jukkrapong Pinyo, Hiroshi Hara, Tohru Hir. Diet-induced obesity enhances postprandial glucagon-like peptide-1 secretion in Wistar rats, but not in diabetic Goto-Kakizaki rats. The British journal of nutrition. vol 126. issue 4. 2021-12-07. PMID:33143769. |
glucagon-like peptide-1 (glp-1) is postprandially secreted from enteroendocrine l-cells and enhances insulin secretion. |
2021-12-07 |
2023-08-13 |
rat |
| Jukkrapong Pinyo, Hiroshi Hara, Tohru Hir. Diet-induced obesity enhances postprandial glucagon-like peptide-1 secretion in Wistar rats, but not in diabetic Goto-Kakizaki rats. The British journal of nutrition. vol 126. issue 4. 2021-12-07. PMID:33143769. |
postprandial glucose, glp-1 and insulin responses in wistar rats fed the hfs diet (wh) were higher than wistar rats fed the control diet (wc). |
2021-12-07 |
2023-08-13 |
rat |
| Jukkrapong Pinyo, Hiroshi Hara, Tohru Hir. Diet-induced obesity enhances postprandial glucagon-like peptide-1 secretion in Wistar rats, but not in diabetic Goto-Kakizaki rats. The British journal of nutrition. vol 126. issue 4. 2021-12-07. PMID:33143769. |
although gk rats fed the hfs diet (gh) had higher glycaemic responses than gk rats fed the control diet (gc), these groups had similar postprandial glp-1 and insulin responses throughout the study. |
2021-12-07 |
2023-08-13 |
rat |
| Jari-Pekka Klemettilä, Anssi Solismaa, Niko Seppälä, Mari Hämäläinen, Eeva Moilanen, Esa Leinonen, Olli Kampma. Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine. Psychiatry research. vol 306. 2021-12-06. PMID:34610543. |
glucagon-like peptide-1 (glp-1) is involved in insulin secretion, regulation of satiety, inhibition of food intake, and inhibition of gastric emptying. |
2021-12-06 |
2023-08-13 |
Not clear |
| Jari-Pekka Klemettilä, Anssi Solismaa, Niko Seppälä, Mari Hämäläinen, Eeva Moilanen, Esa Leinonen, Olli Kampma. Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine. Psychiatry research. vol 306. 2021-12-06. PMID:34610543. |
high serum levels of glp-1 correlated significantly with higher levels of visfatin, leptin, insulin, homa-ir, higher bmi, and weight change among men. |
2021-12-06 |
2023-08-13 |
Not clear |
| Jonathan D Watkins, Françoise Koumanov, Javier T Gonzale. Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review. Advances in nutrition (Bethesda, Md.). vol 12. issue 6. 2021-12-03. PMID:34192748. |
glp-1 potentiates glucose-dependent insulin secretion from the pancreatic β cells and promotes satiety. |
2021-12-03 |
2023-08-13 |
human |
| Olivia M Hopton, Nancee V Waterbury, Jason A Egge, Brian C Lun. Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin. Pharmacotherapy. 2021-12-03. PMID:34807465. |
clinical impact of glp-1 receptor agonists in veterans receiving basal-bolus insulin. |
2021-12-03 |
2023-08-13 |
Not clear |
| Maigen Bethea, Nadejda Bozadjieva-Kramer, Darleen A Sandova. Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion. Endocrinology. vol 162. issue 10. 2021-12-02. PMID:34318874. |
further, other studies have demonstrated the ability of glucagon to impact insulin secretion by acting through the glp-1 receptor. |
2021-12-02 |
2023-08-13 |
Not clear |
| Maigen Bethea, Nadejda Bozadjieva-Kramer, Darleen A Sandova. Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion. Endocrinology. vol 162. issue 10. 2021-12-02. PMID:34318874. |
herein, this review will update the current understanding of the role of glucagon and α-cell-derived glp-1, placing emphasis on their roles in regulating glucose homeostasis, insulin secretion, and β-cell mass. |
2021-12-02 |
2023-08-13 |
Not clear |
| Hung-Yuan L. Revisiting the Strategies for the Pharmacological Management of Type 2 Diabetes- from Glycemic Control, Organ Protection, Safety to Weight Reduction. Journal of diabetes investigation. 2021-12-01. PMID:34850594. |
in the last decade, various new anti-diabetic drugs have been developed, including dipeptidyl peptidase-4 (dpp-4) inhibitors, sodium-glucose cotransporter 2 (sglt2) inhibitors, glucagon-like peptide-1 receptor agonists (glp-1 ras) and several insulin analogues. |
2021-12-01 |
2023-08-13 |
Not clear |
| Amisha Wallia, Matthew J O'Brien, David T Liss, Raymond H Kang, Andrew J Cooper, Amy Gilmer, Ronald T Ackerman. Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population. Mayo Clinic proceedings. Innovations, quality & outcomes. vol 5. issue 3. 2021-11-30. PMID:34195559. |
we conducted a retrospective cohort study analyzing national administrative data from adults with type 2 diabetes mellitus who started a second-line diabetes medication (sulfonylureas [sfus], thiazolidinediones [tzds], glucagon-like peptide 1 [glp-1] agonists, dipeptidyl peptidase 4 [dpp-4] inhibitors, basal insulin, or sodium-glucose contransporter 2 [sglt-2] inhibitors) between april 1, 2011 and september 30, 2015 (n=43,288) and compared rates of hypoglycemia and amcs. |
2021-11-30 |
2023-08-13 |
Not clear |
| Amisha Wallia, Matthew J O'Brien, David T Liss, Raymond H Kang, Andrew J Cooper, Amy Gilmer, Ronald T Ackerman. Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population. Mayo Clinic proceedings. Innovations, quality & outcomes. vol 5. issue 3. 2021-11-30. PMID:34195559. |
most patients (24,506 [56.6%]) were prescribed sulfonylurea as second-line treatment, followed by dpp-4 inhibitors (7953 [18.4%]), glp-1 agonists (3854 [8.9%]), basal insulin (2542 [5.9%]), sglt-2 inhibitors (2537 [5.9%), and tzds (1896 [4.4%]). |
2021-11-30 |
2023-08-13 |
Not clear |
| Enrique Z Fisman, Alexander Tenenbau. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovascular diabetology. vol 20. issue 1. 2021-11-30. PMID:34819089. |
glp-1 stimulates insulin secretion, inhibits glucagon secretion at pancreatic α cells and has also extrapancreatic influences as slowing of gastric emptying which increases the feeling of satiety. |
2021-11-30 |
2023-08-13 |
Not clear |